Hereditary Hemochromatosis Manifesting After Treatment of Paroxysmal Nocturnal Hemoglobinuria With Eculizumab

被引：0
|
作者：
Elliott, Elizabeth [1 ]
Waheed, Salman [2 ]
Syed, Sahr [3 ]
Eswaran, Sheila [4 ]
Gregory, Stephanie [5 ]
Shammo, Jamile [5 ]
机构：
[1] Rush Univ, Med Ctr, Dept Internal Med, 1653 W Congress Pkway, Chicago, IL 60612 USA
[2] Rush Univ, Med Ctr, Div Hematol & Oncol, Chicago, IL 60612 USA
[3] Rush Univ, Med Ctr, Dept Pathol, Chicago, IL 60612 USA
[4] Rush Univ, Med Ctr, Sect Hepatol, Chicago, IL 60612 USA
[5] Rush Univ, Med Ctr, Sect Hematol, Chicago, IL 60612 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2018年 / 18卷 / 01期
关键词：
Anticomplement C5 therapy; Hemoglobinuria; Hemolysis; Iron metabolism; Iron overload; APLASTIC-ANEMIA; DIAGNOSIS; GUIDELINES; MANAGEMENT; IRON;
D O I：
10.1016/j.clml.2017.09.021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：E9 / E12
页数：4
相关论文
共 50 条
  • [21] Eculizumab: A novel therapy for paroxysmal nocturnal hemoglobinuria
    Zareba, Karolina M.
    DRUGS OF TODAY, 2007, 43 (08) : 539 - 546
  • [22] Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
    Hillmen, Peter
    Szer, Jeff
    Weitz, Ilene
    Roeth, Alexander
    Hoechsmann, Britta
    Panse, Jens
    Usuki, Kensuke
    Griffin, Morag
    Kiladjian, Jean-Jacques
    de Castro, Carlos
    Nishimori, Hisakazu
    Tan, Lisa
    Hamdani, Mohamed
    Deschatelets, Pascal
    Francois, Cedric
    Grossi, Federico
    Ajayi, Temitayo
    Risitano, Antonio
    de la Tour, Regis Peffault
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (11): : 1028 - 1037
  • [23] Extravascular hemolytic attack after eculizumab therapy for paroxysmal nocturnal hemoglobinuria
    Tomita, Akihiro
    Shirasugi, Yukari
    Ito, Takahiko
    Tsurumi, Hisashi
    Naoe, Tomoki
    ANNALS OF HEMATOLOGY, 2012, 91 (07) : 1139 - 1141
  • [24] Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
    Rother, Russell P.
    Rollins, Scott A.
    Mojcik, Christopher F.
    Brodsky, Robert A.
    Bell, Leonard
    NATURE BIOTECHNOLOGY, 2007, 25 (11) : 1256 - 1264
  • [25] Eculizumab treatment in pregnant women with paroxysmal nocturnal hemoglobinuria: A Polish experience
    Czyz, Jaroslaw
    Szukalski, Lukasz
    Szukalska, Adriana
    Budziszewska, Bozena Katarzyna
    Lech-Maranda, Ewa
    Zdziarska, Joanna
    Sacha, Tomasz
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2022, 31 (06): : 707 - 710
  • [26] Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
    Russell P Rother
    Scott A Rollins
    Christopher F Mojcik
    Robert A Brodsky
    Leonard Bell
    Nature Biotechnology, 2007, 25 : 1256 - 1264
  • [27] Eculizumab Treatment Improves Outcomes of Pregnancy in Patients with Paroxysmal Nocturnal Hemoglobinuria
    Kelly, Richard J.
    Hoechsmann, Britta
    Kulasekararaj, Austin
    de Guibert, Sophie
    Roeth, Alexander
    Weitz, Ilene C.
    Armstrong, Elina
    Hill, Anita
    Risitano, Antonio M.
    Patriquin, Christopher J.
    Terriou, Louis
    Muus, Petra
    Turner, Michelle P.
    Schrezenmeier, Hubert
    Szer, Jeffrey
    de latour, Regis Peffault
    BLOOD, 2014, 124 (21)
  • [28] Eculizumab treatment improved renal hemosiderosis in a patient with paroxysmal nocturnal hemoglobinuria
    Seiko Iki
    Kazuyuki Ohgi
    Kenshi Suzuki
    International Journal of Hematology, 2017, 105 : 231 - 232
  • [29] Extravascular hemolytic attack after eculizumab therapy for paroxysmal nocturnal hemoglobinuria
    Akihiro Tomita
    Yukari Shirasugi
    Takahiko Ito
    Hisashi Tsurumi
    Tomoki Naoe
    Annals of Hematology, 2012, 91 : 1139 - 1141
  • [30] FDA Report: Eculizumab (Soliris®) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
    Dmytrijuk, Andrew
    Robie-Suh, Kathy
    Cohen, Martin H.
    Rieves, Dwaine
    Weiss, Karen
    Pazdur, Richard
    ONCOLOGIST, 2008, 13 (09): : 993 - 1000
12345